Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from bictegravir/emtricitabine/tenofovir alafenamide to dolutegravir/lamivudine in virologically suppressed older adults with HIV
NL-OMON60357Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dolutegravir and lamivudine in Human immunodeficiency virus infection type 1, sponsored by ViiV Healthcare. Primary endpoint: Plasma HIV-1 RNA at or above 50 copies/mL at Week 48. Started Jan 2024; status: completed.
02
Drugs
dolutegravirlamivudine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on NL-OMON60357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60357.